Grading system for lymph vessel tumor emboli: Significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapy

Modern Pathology

Volumn 23, Issue 4, 2010, Pages 581-592

  Hasebe, Takahiro ^a   Tamura, Nobuko ^b   Iwasaki, Motoki ^c   Okada, Nao ^b   Akashi Tanaka, Sadako ^b   Hojo, Takashi ^b   Shimizu, Chikako ^b   Adachi, Masashi ^b   Fujiwara, Yasuhiro ^b   Shibata, Tatsuhiro ^d   Sasajima, Yuko ^b   Tsuda, Histoshi ^b   Kinoshita, Takayuki ^b  

^a Center for Cancer Control and Information Services   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Breast cancer; Histology; Lymph vessel; P53; Prognosis

Indexed keywords

PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 77950516088     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.3     Document Type: Article

References (26)

1. Lauria R, Perrone F, Carlomagno C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995;76:1772-1778.
2. Nime FA, Rosen PP, Tzvi Thaler H, et al. Prognostic significance of tumor emboli intramammary lymphatics in patients with mammary carcinoma. Am J Surg Pathol 1977;1:25-30.
3. Hasebe T, Sasaki S, Imoto S, et al. Characteristics of tumors in lymph vessels play an important role in the tumor progression of invasive ductal carcinoma of the breast: a prospective study. Mod Pathol 2002; 15:904-913. (Pubitemid 36575875)
4. Hoshida T, Isaka N, Hagendoorn J, et al. Imaging steps of lymphatic metastasis reveals that vascular endothe-lilal growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 2006;66:8065-8075. (Pubitemid 44299172)
5. Yamauchi C, Hasebe T, Iwasaki M, et al. Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance. Hum Pathol 2007;38:247-259. (Pubitemid 46096549)
6. Hasebe T, Yamauchi C, Iwasaki M, et al. Grading system for lymph vessel tumor emboli for prediction of the outcome of invasive ductal carcinoma of the breast. Hum Pathol 2008;39:427-436. (Pubitemid 351193070)
7. Tamura N, Hasebe T, Okada N, et al. Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy. Cancer Sci 2009;100:1823-1833.
8. Hasebe T, Tamura N, Okada N, et al. p53 expression in tumor stromal fibroblasts is closely associated with the nodal metastasis and the outcome of patients with invasive ductal carcinoma who received neoad-juvant therapy. Hum Pathol 2009;41:262-270.
9. Sobin LH, Wittekind Ch. UICC International Union Against Cancer. TNM classification of malignant tumors. In: Sobin LH and Wittekind Ch (eds). 6th edn. Wiley-Liss: Geneva, 2002, pp 131-141.
10. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11:359-377.
11. Gilchrist KW, Gray R, Fowble B, et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 eastern cooperative oncology group patients. J Clin Oncol 1993;11:1929-1935. (Pubitemid 23304618)
12. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 1998;49:195-208. (Pubitemid 28416785)
13. Hasebe T, Sasaki S, Imoto S, et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol 2002;15:502-516. (Pubitemid 34521399)
14. Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer 1977; 40:574-587. (Pubitemid 8175484)
15. Fisher B. Adjuvant chemotherapy in the primary management of breast cancer. Med Clin North Am 1977;61:953-965. (Pubitemid 8176832)
16. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology 2005;46:396-402. (Pubitemid 40516755)
17. Niakosari F, Kahn HJ, Marks A, et al. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohisto-chemical marker of lymphatic endothelium. Arch Dermatol 2005;141:440-444. (Pubitemid 40547402)
18. Allred DC, Harvey JM, Berardo MD, et al. Prognostic and predictive factors in breast cancer by immunohis-tochemical analysis. Mod Pathol 1998;11:155-168. (Pubitemid 28144151)
19. Harvey JM, Clark GM, Osborne K, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
20. Mohsin S, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-1554. (Pubitemid 39627082)
21. Badve SS, Baehner FL, Gray RP, et al. Estrogen-and progesterone-receptor status in ECOG2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008;26:2473-2481.
22. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206. (Pubitemid 23046895)
23. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
24. Westbrook L, Manuvakhova M, Kern FG, et al. Cks1 regulates cdk1 expression: a novel role during mitotic entry in breast cancer cells. Cancer Res 2007;67:11393-11401. (Pubitemid 350248567)
25. Nakamura Y, Tanaka F, Haraguchi N, et al. Clinico-pathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. Br J Cancer 2007;97:543-549. (Pubitemid 47258456)
26. Budhram-Mahadeo VS, Irshad S, Bowen S, et al. Proilferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuro-blastoma and breast cancer cells. Br J Cancer 2008; 27:145-154.